Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
GANXthis companyGain Therapeutics, Inc.	$1.07	-5.28×	5.72×	0×	-4.48×	-46.1%	0.0%	0.0%	0.0%	-108.6%	-95.0%	-17.4%	0.04×	1.05×	0×	6.63×	0.0%	3	-6.34	2	C
ACETAdicet Bio, Inc.	$3.11	-0.5×	0.36×	0×	-0.31×	-8.6%	0.0%	0.0%	0.0%	-73.4%	-70.2%	-167.1%	0.09×	0.22×	-3,392.06×	7.47×	0.0%	1	-6.93	3	B-
CRVOCervoMed Inc.	$1.41	-2.65×	3.92×	0×	-2.34×	-51.0%	0.0%	0.0%	0.0%	-148.0%	-151.0%	-32.8%	0×	0.31×	0×	4.84×	0.0%	2	-3.92	2	C
FBIOFortress Biotech, Inc.	$1.96	-54.3×	2.05×	1.61×	-4.81×	-588.7%	66.9%	-111.0%	10.8%	13.7%	-50.0%	-64.4%	1.49×	0.25×	-8.06×	2.49×	0.7%	6	0.11	4	A
LITSLite Strategy, Inc.	$1.01	-0.45×	0.77×	0×	-2.13×	-83.7%	0.0%	0.0%	0.0%	-170.9%	-29.5%	-28.6%	0×	0.47×	0×	5.74×	0.0%	1	0.13	2	C
NRXPNRx Pharmaceuticals, Inc.	$2.42	-2.02×	-3.64×	47.35×	-1.83×	-67.8%	58.8%	-1324.4%	-2336.5%	179.6%	106.0%	-24.3%	-0.04×	0.26×	-24.18×	0.31×	0.0%	4	-13.9	2	C+
Peer median	—	-2.02×	0.77×	0×	-2.13×	-67.8%	0.0%	0.0%	0.0%	-73.4%	-50.0%	-32.8%	0×	0.26×	-8.06×	4.84×	0.0%	2	-3.92	2	—